{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:08:36Z","timestamp":1770966516604,"version":"3.50.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"s3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J INFECT DIS"],"published-print":{"date-parts":[[2008,5,15]]},"DOI":"10.1086\/533418","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T13:03:06Z","timestamp":1209560586000},"page":"S261-S271","source":"Crossref","is-referenced-by-count":22,"title":["Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions"],"prefix":"10.1093","volume":"197","author":[{"given":"Joseph\u00a0J.","family":"Eron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"rf1_262","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"rf2_263","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68887-9"},{"key":"rf3_264","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Office of the AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: US Department of Health and Human Services, 2006. Available at: http:\/\/AIDSinfo.nih.gov\/guidelines\/. Accessed 22 January 2007."},{"key":"rf4_265","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.7.827"},{"key":"rf5_266","doi-asserted-by":"publisher","DOI":"10.1310\/0XH7-F2V2-1K0R-NU2W"},{"key":"rf6_267","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16589-6"},{"key":"rf7_268","doi-asserted-by":"publisher","DOI":"10.1086\/508655"},{"key":"rf8_269","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000174929.87015.d6"},{"key":"rf9_270","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035103"},{"key":"rf10_271","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000242450.74779.ee"},{"key":"rf11_272","doi-asserted-by":"publisher","DOI":"10.1086\/496892"},{"key":"rf12_273","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067710"},{"key":"rf13_274","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000194131.43382.19"},{"key":"rf14_275","doi-asserted-by":"crossref","unstructured":"Hicks CB, Cahn P, Cooper DA, etal Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.","DOI":"10.1016\/S0140-6736(06)69154-X"},{"key":"rf15_276","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60497-8"},{"key":"rf16_277","doi-asserted-by":"publisher","DOI":"10.1086\/500206"},{"key":"rf17_278","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000185313.48933.2c"},{"key":"rf18_279","unstructured":"Miller M, Witmer M, Stillmock K, etal Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract THAA0302]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Vol 2. Geneva: International AIDS Society, 2006:256."},{"key":"rf19_280","unstructured":"Cooper D, Gatell J, Rockstroh J, etal Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus (abstract 104bLB). In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:103."},{"key":"rf20_281","unstructured":"Steigbigel R, Kumar P, Eron J, etal Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105bLB]. BENCHMRK-2 Study Group. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:104."},{"key":"rf21_282","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"rf22_283","unstructured":"Mistry GC, Wenning LA, Merschman S, etal Atazanavir and ritonavir increase plasma levels of MK-0518 [abstract P291]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection (Glasgow), 2006."},{"key":"rf23_284","unstructured":"Mayer H, van der Ryst E, Saag M, etal Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual\/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract THLB0215]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Geneva: International AIDS Society, 2006."},{"key":"rf24_285","unstructured":"Lalezari J, Goodrich J, DeJesus E, etal Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from phase 2b\/3 study in the US and Canada [abstract 104bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:103."},{"key":"rf25_286","unstructured":"Nelson M, Fatkenheuer G, Konourina I, etal Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract 104aLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:102."},{"key":"rf26_287","unstructured":"Lalezari J, Goodrich J, DeJesus E, etal Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract H-718a]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007."},{"key":"rf27_288","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00712-06"},{"key":"rf28_289","first-page":"S83","volume":"11","author":"De Meyer S","year":"2006","journal-title":"Antivir Ther"},{"key":"rf29_290","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4680-4686.2004"},{"key":"rf30_291","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61047-2"},{"key":"rf31_292","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61048-4"},{"key":"rf32_293","unstructured":"Boehringer Ingelheim Pharmaceuticals. Aptivus prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2006."},{"key":"rf33_294","doi-asserted-by":"publisher","DOI":"10.1086\/508353"},{"key":"rf34_295","doi-asserted-by":"publisher","DOI":"10.1086\/508352"},{"key":"rf35_296","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328013d9d7"},{"key":"rf36_297","first-page":"S34","volume":"12","author":"Vingerhoets J","year":"2007","journal-title":"Antivir Ther"},{"key":"rf37_298","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000218542.08845.b2"},{"key":"rf38_299","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200412150-00009"},{"key":"rf39_300","doi-asserted-by":"publisher","DOI":"10.1086\/430709"},{"key":"rf40_301","unstructured":"DeMasi R, Thommes J, Graham N. Currently marketed nucleos(t)ides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted PIs (PI\/r) in triple class experienced patients (TEPs) [abstract THPE0125]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Vol 2. Geneva: International AIDS Society, 2006:314."},{"key":"rf41_302","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","volume":"9","author":"Vandamme AM","year":"2004","journal-title":"Antivir Ther"},{"key":"rf42_303","doi-asserted-by":"publisher","DOI":"10.1086\/375597"},{"key":"rf43_304","unstructured":"Little SJ, Koelsch KK, Ignacio CC, etal Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy [abstract 36LB]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004."},{"key":"rf44_305","doi-asserted-by":"publisher","DOI":"10.1086\/519164"},{"key":"rf45_306","doi-asserted-by":"publisher","DOI":"10.1086\/496984"},{"key":"rf46_307","first-page":"119","volume":"15","author":"Johnson VA","year":"2007","journal-title":"Top HIV Med"},{"key":"rf47_308","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","volume":"21","author":"Shafer RW","year":"2007","journal-title":"AIDS"},{"key":"rf48_309","doi-asserted-by":"publisher","DOI":"10.1086\/420789"},{"key":"rf49_310","unstructured":"Wheeler W, Mahle K, Bodnar U, etal Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 [abstract 648]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:305."},{"key":"rf50_311","unstructured":"Wensing AM, Vercauteren J, Vijver DA, etal Transmission of HIV drug resistance in Europe [abstract TUAB00101]. SPREAD Programme. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Vol 2. Geneva: International AIDS Society, 2006:261."},{"key":"rf51_312","doi-asserted-by":"publisher","DOI":"10.1086\/528802"},{"key":"rf52_313","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.180"},{"key":"rf53_314","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32805e8764"},{"key":"rf54_315","doi-asserted-by":"publisher","DOI":"10.1086\/425424"},{"key":"rf55_316","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00010"},{"key":"rf56_317","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00009"},{"key":"rf57_318","doi-asserted-by":"publisher","DOI":"10.1086\/428852"},{"key":"rf58_319","unstructured":"Lundgren JD. Progression of HIV-related disease or death (POD) in the randomised SMART study: why was the risk of POD greater in the CD4-guided (re-initiate ART at CD4 <250 cells\/mul) drug conservation (DC) vs the virological suppression (VS) arm [abstract WEAB0203]? SMART Study Group. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Vol 2. Geneva: International AIDS Society, 2006:7."},{"key":"rf59_320","unstructured":"Phillips A, Carr A, Neuhaus J, etal Interruption of ART and risk of cardiovascular disease: findings from SMART [abstract 41]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007:79."},{"key":"rf60_321","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69153-8"},{"key":"rf61_322","doi-asserted-by":"publisher","DOI":"10.1086\/508289"},{"key":"rf62_323","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000181322.17679.b2"},{"key":"rf63_324","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"rf64_325","doi-asserted-by":"crossref","unstructured":"Kaufmann DE, Lichterfeld M, Altfeld M, etal Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.","DOI":"10.1371\/journal.pmed.0010036"},{"key":"rf65_326","doi-asserted-by":"publisher","DOI":"10.1086\/506364"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/197\/Supplement_3\/S261\/18052459\/197-Supplement_3-S261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:35:53Z","timestamp":1684370153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/533418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,15]]},"references-count":65,"journal-issue":{"issue":"s3","published-print":{"date-parts":[[2008,5,15]]}},"alternative-id":["10.1086\/533418"],"URL":"https:\/\/doi.org\/10.1086\/533418","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,15]]}}}